Translational epilepsy research in an academic setting | neuroscience, drug discovery, zebrafish, electrophysiology, cell therapy, precision medicine and more
Salk Institute scientist Shrek Chalasani has been awarded up to $41.3 million from ARPA-H to advance a breakthrough technology he pioneered, sonogenetics, which uses ultrasound to precisely control cells within the body.
This funding will help transform the Chalasani lab’s discovery into a potential noninvasive therapy for a range of conditions, including peripheral neuropathies. By enabling targeted control of mammalian cells without surgery, sonogenetics could redefine how we treat disease.
Learn more: https://t.co/BjzB32CbaK
#SalkInstitute #ARPAH #Sonogenetics #Neuroscience #BiomedicalInnovation
This #FluorescenceFriday comes from the @BarabanLab at UCSF: a new paper by @joseanemarafiga et al. sheds light on how dysregulation in the C1qa gene, which has been linked to neurological disorders like #epilepsy, affects inhibitory neural circuits. (1/4) 🧵
A researchers’ propensity for risky projects is passed down to their doctoral students — and stays with trainees after they leave the laboratory
https://t.co/I71N9jl5sz
More than five years later, @Cronutt1 is still seizure-free and living his best life @sixflagsDK after receiving an experimental therapy with transplanted interneuron progenitor cells developed by the @BarabanLab: https://t.co/1Mx01gBImz
@UCSF@Claire_Simeone@UCI_EpiCenter
Example of the cost of the government shutdown. The NIH study panel I'm serving was postponed. Ended up running with Dec 24, 29, and Jan 2 deadlines. My wife of 30+ years has drawn the line - no more NIH panels. She tolerated weekends, but holiday time was a bridge too far.
The 2020 chemistry laureate Emmanuelle Charpentier shares her best career advice to the next generation of scientists:
"The general advice I give is always to listen to oneself. It’s important to listen to oneself and follow the gut feeling, follow the intuition. In research, it is really important to follow what one likes to do. I liked different topics, and it was difficult to choose. But I think what helps a lot is just to enjoy the science and to see what the science can bring. Focus on this and really trigger the trust in oneself, the sense of curiosity of what we like to do and the joy of the science. This is important because it allows you to deal with the rest. So, they have to learn all these aspects, to see that the rest is little steps that may not work perfectly, but that, at the end of the day, make the beauty of this work. We are very privileged to be able to ask questions and work on what we like to work with."
Read our full interview with Charpentier: https://t.co/m62knmw5MW
About 0.1 percent of the global population, some 8.8 million people, identifies as scientists, which means only a small fraction of people personally know a scientist. https://t.co/UEqxchLrGo
Would be perhaps useful to point out that neural organoids are not miniature brains and that they model fetal stages of parts of the human brain during development (rather than aging or rejuvenation). At these stages, especially in cortical organoids, neural activity is largely driven by spontaneous glutamatergic release and network synchronization typical of early circuits.
Today, we announced that open-label extension data from Harmony Biosciences’ ongoing Phase 3 trial investigating a potential treatment of Dravet syndrome is being presented at the American Epilepsy Society Annual Meeting in Atlanta today. The data shows clinical meaningful reductions in seizure activity in participants with #Dravet syndrome along with a favorable safety profile. Learn more: https://t.co/qX8zHfjUCg
#AES2025
#EpilepsyAwareness
#ClinicalTrials
#RareDisease
#DravetSyndrome
#Innovation
#EmpathyAndInnovation
The gavel has been passed! Many thanks to Dr. Howard Goodkin for a year of exemplary service and congratulations to Dr. Jack Parent, our incoming AES President for 2026! #AES2025
Our Harmony Biosciences team is excited to be at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta! We are looking forward to joining the #epilepsy community and connecting with leaders across healthcare, research, and advocacy. Come say “hello” if you’re there!
#AES2025
#EpilepsyAwareness
#ClinicalTrials
#RareDisease
#DravetSyndrome
#Innovation
#EmpathyAndInnovation
Earlier today, we announced that we will present new open label extension data from Harmony Biosciences’ rare #epilepsy pipeline at the 2025 American Epilepsy Society (AES) Annual Meeting. Poster presentations will highlight data in an ongoing Phase 3 clinical study for the treatment of #Dravet syndrome. Learn more: https://t.co/1lQ0yTKUL9
#AES2025
#EpilepsyAwareness
#ClinicalTrials
#RareDisease
#DravetSyndrome
#Innovation
#EmpathyAndInnovation
save for some caveats, i agree with this. i find solace in the fact that biology is unforgiving and if your tech is built on bs hype it will eventually show. sad part is the wasted resources and ultimately, the false hope given to consumers of biotech products.